The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Mohamadi, F., Richards, N. G. J., Guida, W. C., Liskamp, R., Lipton, M., Caufield, C., Chang, G., Hendrickson, T., & Still, W. C. (1990) · Journal of Computational Chemistry · doi:10.1002/jcc.540110405 · Cited by 3,757
Molecular mechanics. The MM3 force field for hydrocarbons. 1
Allinger, N. L., Yuh, Y. H., & Lii, J. H. (1989) · Journal of the American Chemical Society · doi:10.1021/ja00205a001 · Cited by 2,810
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Harris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B. (2009) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1296 · Cited by 877
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
He, B., Gampe, R. T., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., & Wilson, E. M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.036 · Cited by 295
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., & Tilley, W. D. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00525 · Cited by 240
Self-citationRecognition and Accommodation at the Androgen Receptor Coactivator Binding Interface
Hur, E., Pfaff, S. J., Payne, E. S., Grøn, H., Buehrer, B. M., & Fletterick, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020274 · Cited by 234
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
Estébanez-Perpiñá, E., Moore, J. M. R., Mar, E., Delgado-Rodrigues, E., Nguyen, P., Baxter, J. D., Buehrer, B. M., Webb, P., Fletterick, R. J., & Guy, R. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m407046200 · Cited by 164
Shaginian, A., Whitby, L. R., Hong, S., Hwang, I., Farooqi, B., Searcey, M., Chen, J., Vogt, P. K., & Boger, D. L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja810025g · Cited by 147
Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction
Plante, J. P., Burnley, T., Malkova, B., Webb, M. E., Warriner, S. L., Edwards, T. A., & Wilson, A. J. (2009) · Chemical Communications · doi:10.1039/b908207g · Cited by 141
Peptidomimetics and Peptide Backbone Modifications
Ahn, J., Boyle, N., MacDonald, M., & Janda, K. D. (2002) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557023405828 · Cited by 124
Self-citationEvidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Centenera, M. M., Gillis, J. L., Hanson, A. R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0782 · Cited by 108
Self-citationNovel Amphiphilic α-Helix Mimetics Based on a Bis-benzamide Scaffold
Marimganti, S., Cheemala, M. N., & Ahn, J. (2009) · Organic Letters · doi:10.1021/ol901785v · Cited by 85
Self-citationFunctional and biological properties of the nuclear receptor coregulator PELP1/MNAR
Vadlamudi, R. K., & Kumar, R. (2007) · Nuclear Receptor Signaling · doi:10.1621/nrs.05004 · Cited by 79
Facile synthesis of benzamides to mimic an α-helix
Ahn, J., & Han, S.-Y. (2007) · Tetrahedron Letters · doi:10.1016/j.tetlet.2007.03.108 · Cited by 65
Self-citationCoactivator selective regulation of androgen receptor activity
Agoulnik, I. U., & Weigel, N. L. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.007 · Cited by 64
Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis
Chakravarty, D., Roy, S. S., Babu, C. R., Dandamudi, R., Curiel, T. J., Vivas‐Mejía, P. E., Lopez‐Berestein, G., Sood, A. K., & Vadlamudi, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2718 · Cited by 54
Controlling Curvature in a Family of Oligoamide α‐Helix Mimetics
Saraogi, I., Incarvito, C. D., & Hamilton, A. D. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200803778 · Cited by 53
Androgen Receptor Coactivators and Prostate Cancer
Agoulnik, I. U., & Weigel, N. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_23 · Cited by 52
Central Role for PELP1 in Nonandrogenic Activation of the Androgen Receptor in Prostate Cancer
Yang, L., Ravindranathan, P., Ramanan, M., Kapur, P., Hammes, S. R., Hsieh, J., & Raj, G. V. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1101 · Cited by 50
Self-citationNair, S. S., Guo, Z., Mueller, J. M., Koochekpour, S., Qiu, Y., TEKMAL, R. R., Schüle, R., Kung, H.-J., Kumar, R., & Vadlamudi, R. K. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0269 · Cited by 46
Significance of PELP1 in ER-Negative Breast Cancer Metastasis
Roy, S. S., Chakravarty, D., Cortez, V. A., Mukhopadhyay, K. D., Bandyopadhyay, A. M., Ahn, J., Raj, G. V., TEKMAL, R. R., Sun, L., & Vadlamudi, R. K. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0456 · Cited by 43
Self-citationSolid-Phase Synthesis of Tris-Benzamides as α-Helix Mimetics
Lee, T.-K., & Ahn, J. (2010) · ACS Combinatorial Science · doi:10.1021/co100056c · Cited by 40
Self-citationHsieh, A. C., Small, E. J., & Ryan, C. J. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70316-9 · Cited by 37
PELP1: A novel therapeutic target for hormonal cancers
Chakravarty, D., TEKMAL, R. R., & Vadlamudi, R. K. (2009) · IUBMB Life · doi:10.1002/iub.287 · Cited by 35
Management of Metastatic Castration-Resistant Prostate Cancer: Recent Advances
Mukherji, D., Eichholz, A., & Bono, J. S. D. (2012) · Drugs · doi:10.2165/11633360-000000000-00000 · Cited by 33
Unraveling the Complexities of Androgen Receptor Signaling in Prostate Cancer Cells
Heemers, H. V., & Tindall, D. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.009 · Cited by 32
Emerging significance of ER-coregulator PELP1/MNAR in cancer.
Nair, S. S., & Vadlamudi, R. K. (2007) · PubMed · doi:10.14670/hh-22.91 · Cited by 26
(1998) · doi:10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10>3.0.co;2-b
Cited by
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Metadata
- Authors
- Ravindranathan, P., Lee, T.-K., Yang, L., Centenera, M. M., Butler, L., Tilley, W. D., Hsieh, J.-T., Ahn, J.-M., & Raj, G. V.
- Venue
- Nature Communications
- Published
- 2013-05-28
- Volume
- 4
- Issue
- 1
- Pages
- 1923-1923
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2165177861
- Cited by
- 257
- References
- 40
- FWCI
- 40.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
